Setipiprant

Setipiprant (ACT-129968, KYTH-105) is a tetrahydropyridoindole derivative that acts as a potent, selective, and orally bioavailable antagonist of the chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2), also designated as the prostaglandin D2 receptor 2 (DP2 or GPR44). The compound binds the human CRTH2 receptor with an IC50 of approximately 6 nanomolar and demonstrates approximately 215-fold selectivity over the prostaglandin D2 receptor 1 (DP1), with no meaningful antagonism of the thromboxane receptor or inhibition of cyclooxygenase-1. CRTH2 is a G-protein-coupled receptor expressed on eosinophils, basophils, type 2 innate lymphoid cells, and T-helper 2 lymphocytes; activation by prostaglandin D2 drives chemotaxis, degranulation, and cytokine release from these cells, positioning CRTH2 antagonism as a mechanistically distinct anti-inflammatory strategy in allergic and type 2 inflammatory disease.

Setipiprant was discovered at Actelion Pharmaceuticals through a lead optimization program focused on improving potency and oral bioavailability within a pyrido[4,3-b]indole scaffold series. The compound advanced through Phase 1 single- and multiple-ascending-dose studies demonstrating favorable tolerability, rapid oral absorption (time to peak concentration approximately 2 to 4 hours), a terminal elimination half-life of 10 to 18 hours, and near-complete recovery of administered radioactivity in a human mass balance study (approximately 88 percent fecal, 12 percent urinary). Approximately 54 percent of administered dose was recovered as unchanged parent compound, indicating that direct fecal excretion rather than hepatic metabolism is the dominant clearance pathway. The two principal circulating metabolites, M7 and M9, are dihydroxy-dihydronaphthalene isomers formed through epoxidation of the naphthyl ring, and neither exceeds 10 percent of parent drug plasma concentrations at steady state.

Actelion advanced setipiprant through Phase 2 and Phase 3 clinical programs in seasonal allergic rhinitis and a Phase 2a proof-of-mechanism study in allergic asthma. In the allergic asthma crossover study (n=18), setipiprant at 1000 mg twice daily for 5 days significantly reduced the allergen-induced late asthmatic response by 25.6 percent (p=0.006) and protected against allergen-induced airway hyperresponsiveness to methacholine (p=0.003). In the Phase 2 seasonal allergic rhinitis trial (n=579), setipiprant 1000 mg twice daily produced statistically significant, dose-related improvement in daytime nasal symptom scores versus placebo (p=0.030), with significant improvements also observed in nighttime nasal symptoms and daytime eye symptoms. However, the Phase 3 confirmatory trial (n=630) at the same dose failed to replicate the Phase 2 efficacy signal on the primary endpoint (p=0.652), despite adequate methodology and a consistent cetirizine active-reference effect. Actelion discontinued development in the allergic rhinitis and asthma indications and redirected anti-inflammatory efforts to a follow-up CRTH2 antagonist.

The compound was subsequently repositioned for androgenetic alopecia following the Garza et al. (2012) demonstration in Science Translational Medicine that prostaglandin D2 synthase and prostaglandin D2 are elevated in the bald scalp of men with androgenetic alopecia and that prostaglandin D2 inhibits hair follicle growth through the CRTH2/GPR44 receptor. Kythera Biopharmaceuticals acquired the rights to setipiprant and submitted an Investigational New Drug application to the FDA in September 2015 (designated KYTH-105). Allergan acquired Kythera in October 2015 for approximately 2.1 billion dollars and conducted a Phase 2a randomized, double-blind, placebo-controlled trial (n=169) of setipiprant 1000 mg twice daily for 24 weeks in men with androgenetic alopecia. The trial did not meet either coprimary endpoint: target area hair count change was 6.7 hairs per square centimeter with setipiprant versus 7.0 with placebo (p=0.92), and subject self-assessment showed no difference (p=0.91). Setipiprant was well tolerated throughout all clinical programs, with headache as the most frequently reported adverse event and no severe or clinically significant safety signals identified across more than 1,500 subjects exposed in clinical trials.

This monograph reviews the chemistry, synthesis, and structural class of setipiprant; the CRTH2/DP2 receptor pharmacology and prostaglandin D2 signaling biology; the comprehensive human pharmacokinetic and metabolic disposition data; the preclinical pharmacology in inflammatory and alopecia models; the clinical evidence base across allergic rhinitis, asthma, and androgenetic alopecia; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and safety profile; and a comparative assessment of five CRTH2/DP2 receptor antagonists (fevipiprant, timapiprant, ramatroban, AZD1981, and BI-671800) against setipiprant on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation. The compound is not approved by any regulatory authority. It is available as a research-grade preparation from multiple chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.